Spyro Mousses’ primary academic affiliation is as Professor at the Translational Genomics Research Institute (TGen), in Phoenix AZ, USA. His scientific background and expertise include developing genomics platforms and computational technologies, with a focus on strategically integrating multiple technologies and scientific resources to engineer innovative solutions that can support drug discovery, translational research, clinical drug development, personalized medicine, and eHealth. He has published on many scientific advances that include new platform technologies, breakthrough genomic discoveries of multiple new cancer genes, new cancer drug treatment strategies, and most recently innovative computational approaches for knowledge computing to enable clinical genomics to be applied to accelerate molecular medicine. Dr. Mousses has extensive experience in leading large multi-disciplinary private/public collaborations and architected partnerships with more than 20 major corporations in the pharmaceutical, biotech, life sciences, and IT industries. He is also an innovation driven entrepreneur with a passion for advancing life-saving scientific innovations to the marketplace. His previous roles include serving as chief scientific officer and co-founder of Systems Medicine Inc (acquired by Cell Therapeutics Inc.), and MedTrust OnLine Inc. (acquired by Annai Systems Inc.). Dr. Mousses received his BSc (Pharmacology and Toxicology), MSc and PhD (Molecular Pathogenesis and Genetics of Cancer), from the University of Toronto, Canada. He served as Staff Scientist at the National Human Genome Research Institute, National Institutes of Health where he led a program in cancer genome scanning and high throughput technology development. He joined the Translational Genomics Research Institute (TGen), at the inception of the Institute as one of the founding scientists, contributing to the building and directing the Cancer Drug Development Laboratory, the Pharmaceutical Genomics Division, and most recently appointed to directs the Center for BioIntelligence and Vice President in the Office of Innovation.